Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
The French-Danish biotech company Onxeo has raised EUR 15 million (USD 16.73 million) in a recently completed capital increase. The goal was EUR 12 million (USD 13.39 million), but the fundraising brought the company’s management a pleasant surprise.
The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Novo Nordisks lægemiddel semaglutid kan måske være selskabets nøgle til de mange milliarder, der ligger i medicinsk behandling af svær overvægt i USA. Det mener Nordeas medicinalanalytiker, der påpeger at de nye data for midlet kan være en game changer.
Det danske biotekselskab Cytovac har for nylig rejst små 10 mio. kr., men der skal yderligere 50 mio. kr. i kassen inden udgangen af 2017, siger adm. direktør Martin Roland Jensen. Samtidig kan man, hvis alt går vel, forvente de første data fra et vigtigt fase 2-studie allerede i år.